UNSPSC 51384209: Loxoprofen sodium dihydrate

This classification denotes a cyclooxygenase inhibitor with the molecular formula C15H17O3.Na.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z2DR42L11Y, chemically known as benzeneacetic acid, .alpha.-methyl-4-((2-oxocyclopentyl)methyl)-, sodium salt, hydrate (1:1:2), but more generally known as loxoprofen sodium dihydrate, which bears US NIH Compound Identifier 157322.

European Medicines Agency schedules loxoprofen sodium dihydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08609MIG. Most nations, for tariff purposes, schedule loxoprofen sodium dihydrate under HS 29183000. SMILES: CC(C1CCC(CC1)CC2CCCC2=O)C(=O)[O-].O.O.[NA+].

UNSPSC 51384209 Loxoprofen sodium dihydrate is a Commodity code that in practice covers pharmaceutical active ingredients and finished-form drugs procured by state and local health agencies, though recent state and local solicitations tagged to this code show minimal direct activity for loxoprofen itself. The three recent opportunities associated with the code span naloxone procurement (Seminole County, Florida), direct-to-manufacturer prescription programs (Texas HHS), and multi-source generic pharmaceuticals and OTC products through a cooperative purchasing vehicle (Minnesota Multistate Cooperative Purchasing Alliance), indicating that state and local governments use pharmaceutical codes across a range of health-related supply chains—emergency response drugs, prescription management programs, and bulk generic-drug distribution—rather than for single-active-ingredient procurement. The issuing bodies include county health departments, state human services commissions, and state procurement offices administering cooperative purchasing agreements that span multiple participating jurisdictions.

Recent activity concentrates in Florida, Texas, and Minnesota. The most concrete opportunity is Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida—a fixed-price, two-year contract with one-year renewal option requiring E-Verify compliance and standard insurance coverage. Texas HHS issued RFI HHS0017013 (April 3, 2026) to explore direct-to-manufacturer prescription programs, a preliminary market-intelligence solicitation with no formal award timeline. The Minnesota Department of Administration, through MMCAP, released RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed via three authorized wholesalers, with evaluation weighting 75 percent on price competitiveness, effective July 1, 2026. The code shows limited recent activity specifically targeting loxoprofen sodium dihydrate and appears to capture pharmaceutical procurement more broadly when state and local agencies tag opportunities to this taxonomy.